Divis Laboratories Ltd

  • BSE Code : 532488
  • NSE Symbol : DIVISLAB
  • ISIN : INE361B01024
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS

up-arrow 6,623.00 26.50(0.40%)

Open Price ()

6,636.50

Prev. Close ()

6,596.50

Volume (No’s)

200,964

Market Cap ()

175,819.84

Low Price ()

6,567.00

High Price ()

6,636.50

 

Board Meetings

Start Date End Date Purpose
14-May-2026 23-May-2026 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2026 inter alia to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31 2026 and to recommend dividend if any for the financial year 2025-26. Outcome of Board meeting held on May 23, 2026. (As per BSE Announcement dated on: 23.05.2026)
30-Jan-2026 11-Feb-2026 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended December 31 2025. Outcome of Board Meeting held on February 11, 2026. (As per BSE Announcement dated on: 11.02.2026)
27-Oct-2025 07-Nov-2025 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2025 inter alia to consider and approve the unaudited financial results for the quarter and half year ended September 30 2025. Outcome Of Board Meeting (As per BSE Announcement dated on: 07.11.2025)
26-Jul-2025 06-Aug-2025 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2025 inter alia to consider and approve unaudited financial results for the quarter ended June 30 2025. Outcome of Board Meeting held on August 06, 2025. (As per BSE Announcement Dated on 06.08.2025)
08-May-2025 17-May-2025 Divis Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2025 inter alia to consider and approve Audited Financial Results for the Quarter and Year ended March 31 2025 and recommend Dividend for FY2024-25 if any. As per enclosed letter. (As Per BSE Announcement dated on 17.05.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew